N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=8 Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
Primary: Percentatge of Doravirine Dialysis Extraction Ratio (ER) — 34.3 percentage of doravirine dialysis ER
N/A N=19 Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
End Stage Renal Disease
Primary: Mean Systolic Blood Pressure Over the Third Month of Each Treatment Arm — 139; 142 mm Hg
Phase 2 N=11 Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Hyperphosphatemia · Kidney Disease
Primary: Serum Phosphorous Concentration — 2.0; 1.7 mg/dL
N/A N=20 Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Mean Absolute Relative Difference Between CGM Value and Capillary Blood Glucose (Self-monitoring Blood Glucose [SMBG]) — 13.8 percent difference
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Phase 3 N=46 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
Primary Hyperparathyroidism · Parathyroid Adenoma · Parathyroid Hyperplasia
Primary: Change in Lumbar Spine Bone Mineral Density — 0.030; 0.042; -0.016 g/cm^2 — p=< 0.00001
N/A N=6 Intradialytic Drug Removal by Short-daily Hemodialysis
End Stage Renal Disease · Infection
Primary: Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis — 7.2; 7.6 ml/min
Phase 3 N=48 A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
End Stage Renal Failure on Dialysis
Primary: Patients' Adherence to Study Protocol — 22; 24; 19; 19 Participants
N/A N=47 Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
Renal Osteodystrophy
Primary: Percent Reduction in PTH — 27; 10 % change in PTH baseline to 3 months
Phase 2 N=189 Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
COVID-19
Primary: Number of Participants With COVID-19 Infection — 5; 7 participants
Phase 4 N=17 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
End-stage Renal Disease · Cardiovascular Disease
Primary: Pharmacokinetic Parameters of Ranolazine — 0.65 mcg/mL
Phase 4 N=16 Identifying and Treating Depression in Hemodialysis Patients
Depression · Hemodialysis-Induced Symptom
Primary: To Determine the Impact of Directly Observed Weekly Fluoxetine Treatment on Remission of Depression Among Hemodialysis Patients. — 6.6 units on a scale
N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Phase 1 N=24 Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
Infections, Bacterial
Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter